Wednesday - September 9, 2026
FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber
August 26, 2026
BOSTON, Massachusetts, Aug. 26 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:

* * *

FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber

*

#Daraxonrasib is the first approved RAS-targeted therapy in pancreatic cancer

#Approval based primarily on Dana-Farber-led RASolute 302 trial showing daraxonrasib nearly doubled median over . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products